

Product datasheet for **TR316686**

SHP2 (PTPN11) Human shRNA Plasmid Kit (Locus ID 5781)

Product data:

Product Type:	shRNA Plasmids
Product Name:	SHP2 (PTPN11) Human shRNA Plasmid Kit (Locus ID 5781)
Locus ID:	5781
Synonyms:	BPTP3; CFC; JMML; METCD5; NS1; PTP-1D; PTP2C; SH-PTP2; SH-PTP3; SHP2
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	PTPN11 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 5781). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	NM_002834 , NM_080601 , NM_001330437 , NM_002834.1 , NM_002834.2 , NM_002834.3 , NM_002834.4 , NM_080601.1 , NM_080601.2 , BC007869 , BC008692 , BC025181 , BC030949 , NM_080601.3 , NM_002834.5
UniProt ID:	Q06124
Summary:	The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains two tandem Src homology-2 domains, which function as phospho-tyrosine binding domains and mediate the interaction of this PTP with its substrates. This PTP is widely expressed in most tissues and plays a regulatory role in various cell signaling events that are important for a diversity of cell functions, such as mitogenic activation, metabolic control, transcription regulation, and cell migration. Mutations in this gene are a cause of Noonan syndrome as well as acute myeloid leukemia. [provided by RefSeq, Aug 2016]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).